Christopher Furlong Today, we are back to analyzing AstraZeneca ( NASDAQ: AZN ). This year, we published a detailed note commenting on the Fiscal Year 2022 results, and since then, the company has been up by 12.49% (including the dividend payment). Our buy case recap